- Y Diweddaraf sydd Ar Gael (Diwygiedig)
- Pwynt Penodol mewn Amser (15/02/2018)
- Gwreiddiol (a wnaed Fel)
Point in time view as at 15/02/2018.
There are currently no known outstanding effects for the The Blood Safety and Quality Regulations 2005, Paragraph 2.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
2.3. For autologous donations, the measures marked with an asterisk (*) are recommendations only.U.K.
Component | Quality measures required | Acceptable results for quality measures |
---|---|---|
The required frequency of sampling for all measurements shall be determined using statistical process control | ||
Red cells | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 45g per unit | |
Haemolysis | Less than 0.8% of red cell mass at end of the shelf life | |
Red cells, buffy coat removed | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 43 g per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Red cells, leucocyte-depleted | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 40g per unit | |
Leucocyte content | Less than 1 x 106 per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Red cells, in additive solution | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 45g per unit | |
Haemolysis | Less than 0.8% of red cell mass at end of the shelf life | |
Red cells, buffy coat removed, in additive solution | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 43g per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Red cells, leucocyte-depleted, in additive solution | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 40g per unit | |
Leucocyte content | Less than 1 x 106 per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Red cells, apheresis | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis |
Haemoglobin (*) | Not less than 40g per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Whole blood | Volume | Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis 450ml +/- 50ml For paediatric autologous whole blood collections – not to exceed 10.5ml per kg body weight |
Haemoglobin (*) | Not less than 45g per unit | |
Haemolysis | Less than 0.8% of red cell mass at the end of the shelf life | |
Platelets, apheresis | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per single donation are permitted within the limits that comply with validated preparation and preservation conditions | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Platelets, apheresis, leucocyte-depleted | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per single donation are permitted within the limits that comply with validated preparation and preservation conditions | |
Leucocyte content | Less than 1 x 106 per unit | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Platelets, recovered, pooled | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per pool are permitted within limits that comply with validated preparation and preservation conditions | |
Leucocyte content | Less than 0.2 x 109 per single unit (platelet-rich plasma method) Less than 0.05 x 109 per single unit (buffy coat method) | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Platelets, recovered, pooled, leucocyte-depleted | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per pool are permitted within limits that comply with validated preparation and preservation conditions | |
Leucocyte content | Less than 1 x 106 per pool | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Platelets, recovered, single unit | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per single unit are permitted within limits that comply with validated preparation and preservation conditions | |
Leucocyte content | Less than 0.2 x 109 per single unit (platelet-rich plasma method) Less than 0.05 x 109 per single unit (buffy coat method) | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Platelets, recovered, single unit, leucocyte-depleted | Volume | Valid for storage characteristics to maintain product within specifications for pH |
Platelet content | Variations in platelet content per single unit are permitted within limits that comply with validated preparation and preservation conditions | |
Leucocyte content | Less than 1 x 106 per unit | |
pH | [F1Minimum 6.4 corrected for 22°C, at the end of the shelf life] | |
Plasma, fresh-frozen | Volume | Stated volume +/- 10% |
Factor VIIIc(*) | Average (after freezing and thawing): 70% or more of the value of the freshly collected plasma unit | |
Total protein | Not less than 50g/l | |
Residual cellular content(*) | Red cells: less than 6.0 x 109/l Leucocytes: less than 0.1 x 109/l Platelets: less than 50 x 109/l | |
Plasma, fresh-frozen, cryoprecipitate-depleted | Volume | Stated volume +/-10% |
Residual cellular content(*) | Red cells: less than 6.0 x 109/l Leucocytes: less than 0.1 x 109/l Platelets: less than 50 x 109/l | |
Cryoprecipitate | Fribrinogen content(*) | Greater than or equal to 140mg per unit |
Fractor VIIIc content (*) | Greater than or equal to 70 international units per unit | |
Granulocytes, apheresis | Volume | Less than 500ml |
Granulocyte content | Greater than 1 x 1010 granulocytes per unit |
Textual Amendments
F1Words in Sch. Pt. 5 para. 2 Table substituted (18.7.2016) by The Blood Safety and Quality (Amendment) Regulations 2016 (S.I. 2016/604), regs. 1, 2(3)
Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.
Gwreiddiol (Fel y’i Deddfwyd neu y’i Gwnaed): Mae'r wreiddiol fersiwn y ddeddfwriaeth fel ag yr oedd pan gafodd ei deddfu neu eu gwneud. Ni wnaed unrhyw newidiadau i’r testun.
Pwynt Penodol mewn Amser: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Rhychwant ddaearyddol: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Dangos Llinell Amser Newidiadau: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Mae Memoranda Esboniadol yn nodi datganiad byr o ddiben Offeryn Statudol ac yn rhoi gwybodaeth am ei amcan polisi a goblygiadau polisi. Maent yn ceisio gwneud yr Offeryn Statudol yn hygyrch i ddarllenwyr nad oes ganddynt gymhwyster cyfreithiol, ac maent yn cyd-fynd ag unrhyw Offeryn Statudol neu Offeryn Statudol Drafft a gyflwynwyd ger bron y Senedd o Fehefin 2004 ymlaen.
Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:
liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys